Create a comprehensive dataset for financial entity recognition. Label all…
- User
System: Create a comprehensive dataset for financial entity recognition. Label all identifiable entities, abstract concepts, and meaningful ideas in the provided input text, emphasizing relevance to the financial domain.
Ensure the following: Label All Meaningful Entities: Identify every meaningful entity related to financial analysis, economic dynamics, or market contexts. Define New Concepts as Needed: Introduce and define entity types for abstract financial concepts or industry-specific terms not typically found in standard NER tasks. Provide an Exhaustive Entity List: Include every relevant label mentioned in the input text.
Respond in the following format: | | <description of entity group/concept>, | | <description of entity group/concept>, ... Input: User: Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated consistently across age, gender, ethnicity and starting body mass index (BMI).Beneficial effects were seen consistently across measured cardiovascular endpoints with semaglutide 2.4 mg.Risk reductions in MACE were evident soon after initiation, suggesting an effect of semaglutide 2.4 mg beyond weight loss alone. Bagsværd, Denmark, 11 November Assistant:
- Assistant
Semaglutide 2.4 mg | Pharmaceutical Product | A medication referenced for its impact on cardiovascular health and risk reduction in the context of major adverse cardiovascular events. Statistically significant | Statistical Measure | A term used to indicate a result that is unlikely to have occurred by random chance, showing reliability in scientific study inferences. 20% risk reduction | Statistical Outcome | A quantitative measure representing the decrease in risk percentage observed in a treated group versus a control group. Major adverse cardiovascular events (MACE) | Medical/Health Concept | A composite endpoint commonly used in cardiovascular clinical trials including conditions like heart attack and stroke. Risk reductions | Financial/Statistical Concept | A decrease in risk factors or probabilities associated with certain outcomes, relevant in clinical and financial risk assessments. Age, gender, ethnicity, starting body mass index (BMI) | Demographic/Health Factors | Variables considered in clinical studies to assess efficacy across diverse population groups. Cardiovascular endpoints | Medical/Health Metrics | Specific health outcomes used to evaluate the impact of a treatment on cardiovascular health in clinical trials. Bagsværd, Denmark | Geographic Location | Location of significance, possibly indicating the headquarters or relevant site for a pharmaceutical company or clinical trial location. 11 November | Date/Temporal Indicator | Specific date potentially relevant for the timing of an event, announcement, or report release in a financial or clinical context.